Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › GLUE

Monte Rosa Therapeutics

GLUE Rare disease Lead: Phase 2 4 Biotech Distilled articles ↓
CardiovascularDermatologyImmunologyMetabolicOncology Small Molecule

Most recent annual filing: 2026-03-17

Catalyst timeline

8 trackedQuarter catalyst calendar →
  1. next-generation NEK7 MGD and CCNE12026next-generation NEK7 MGD and CCNE1, 2026, notable
  2. MRT-6160 Ph2 start2026MRT-6160 Ph2 start, 2026, routine
  3. second-generation NEK7 MGD IND filing2H 2026second-generation NEK7 MGD IND filing, 2H 2026, notable
  4. MRT-8102 GFORCE-3 Ph2 start4Q 2026/1Q 2027MRT-8102 GFORCE-3 Ph2 start, 4Q 2026/1Q 2027, notable
  5. MRT-9347 IND filing4Q 2026MRT-9347 IND filing, 4Q 2026, notable
  6. MRT-8102 GFORCE-2 Ph2 start1H 2027MRT-8102 GFORCE-2 Ph2 start, 1H 2027, notable
  7. CCNE1 MGD IND filing2027CCNE1 MGD IND filing, 2027, notable
  8. CCNE1 IND filing2027CCNE1 IND filing, 2027, notable

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (7 active programs)

Technology platforms

QuEEN

Quantitative and Engineered Elimination of Neosubstrates — AI/ML-enabled, target-centric molecular glue degrader discovery engine combining geometric deep learning for protein surface characterization, high-throughput screening, structural biology, and proprietary MGD library of 75,000+ compounds. Focused on immunology, inflammation, cardiovascular, oncology, and CNS diseases.

Roche Collaboration Platform · Roche

Strategic collaboration with Roche to identify and develop MGDs against cancer and neurological disease targets using Monte Rosa's QuEEN discovery platform. Monte Rosa leads preclinical discovery; Roche gains exclusive rights for further development upon defined handoff criteria.

Novartis I&I Collaboration Platform · Novartis

Collaboration, option, and license agreement with Novartis for discovery and development of degraders targeting immunology and inflammation programs. Monte Rosa applies QuEEN engine for one licensed I&I program and two optioned preclinical I&I programs; Novartis responsible for development and commercialization.

QuEEN · Novartis

AI/ML-enabled QuEEN engine for the discovery and development of molecular glue degraders (MGDs); focus areas include immunology and inflammation

Biotech Distilled coverage (4)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.